Answers are grounded in this paper and cite their sources.
Shows dose-dependent pharmacokinetics of bulleyaconitine A in male Sprague-Dawley rats, indicating potential variations in drug exposure.
This study was conducted to determine the pharmacokinetic characteristics of bulleyaconitine A (BLA) after oral gavage and intravenous administration of BLA at a single dose of 0.04, 0.12, 0.36 mg/kg (oral) or 0.02 mg/kg (i.v.) in male Sprague-Dawley rats. Plasma concentration profiles were analysed using a non-compartmental pharmacokinetic method. Following i.v. 0.02 mg/kg and oral administration 0.04, 0.12 or 0.36 mg/kg, the geometric mean Cmax values were 19.97, 2.11, 5.11 and 11.47 ng/ml, respectively; the corresponding geometric mean AUC0-t values were 10.50, 3.19, 9.59 and 18.10 ng·h/ml, respectively. The median Tmax values were 0.033, 0.167, 0.167 and 0.167 h, respectively. The terminal elimination half-lives (t1/2) were 1.23, 2.48, 1.93 and 2.17 h, respectively. The results showed that Cmax and AUC0-t increased with increasing doses of BLA. The increase in exposure with increasing dose was lower than expected under conditions of strict proportionality.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: